This procedure has been used successfully to treat thousands of animals suffering from arthritis in the United States (www.vet-stem.com). Recently Dr. Paz published a paper describing scientific mechanisms of this treatment in collaboration with scientists from the University of California San Diego, University of Western Ontario, and Medistem Inc (Ichim et al. Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease. Cell Immunol. 2010 Apr 8).
“I had treatment for my arthritis, I was not wheelchair bound but I was getting there… after stem cell treatment my arthritis symptoms disappeared,” stated Mr. Durrill.
More than 200 people attended the lecture including the general public, patients and medical doctors. The lecture was focused on US and European clinical trials supporting the use of adult stem cells in conditions ranging from multiple sclerosis, to heart failure, to diabetes. A video of part of the lecture is available at www.kiiitv.com.
Dr. Paz commented, “Mr. Durrill suffered from arthritis for more than ten years with severe pain in both knees and hips. He had difficulty standing and limited mobility. After stem cell therapy he started showing significant reduction in pain. Now about a month after therapy he is pain free and can move around easily.”
Drs. Robert Harman, CEO of Vet-Stem and Thomas Ichim, CEO of Medistem, recently released a video discussing their publication on fat stem cell therapy for arthritis. The video is available at www.youtube.com.
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at www.translational-medicine.com.
Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.
